GWP
UTHR icon

Gen-Wealth Partners’s United Therapeutics UTHR Stock Holding History

Gen-Wealth Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-220
Closed -$77.6K – 666
2024
Q4 		$77.6K Hold
220
– – 0.03% 318
2024
Q3 		$79.5K Buy
+220
New +$74.3K 0.03% 318

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Gen-Wealth Partners's UTHR Position: Q1 2025 in Review

Gen-Wealth Partners sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 220 shares — an estimated $77.6K sold.

Gen-Wealth Partners first reported a position in UTHR in Q3 2024 and held it in 2 quarters. The position peaked at $79.5K in Q3 2024. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • Gen-Wealth Partners reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Gen-Wealth Partners sold 220 United Therapeutics shares in Q1 2025, an estimated $77.6K.
  • Gen-Wealth Partners first reported a position in United Therapeutics in Q3 2024 and held it in 2 quarters.
  • Gen-Wealth Partners's United Therapeutics position peaked at $79.5K in Q3 2024.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Gen-Wealth Partners's 13F filing for Q1 2025, filed 13 May 2025.